Conceptual frameworks and key dimensions to support coverage decisions for vaccines.

BACKGROUND Health policy makers often have to face decisions on whether and how to incorporate new vaccines into immunisation plans. This study aims to review and catalogue the relevant current frameworks and taxonomies on vaccines and connect these to the DECIDE Evidence to Decision framework (EtD), a general framework based on evidence-based criteria to guide decision-making on intervention adoption. METHODS We systematically searched MEDLINE, EMBASE, Cochrane Library and funding agency websites from 1990 to 2013. We included systematic reviews and primary studies presenting decision-making tools for community vaccine adoption. We qualitatively summarised the reports by purpose, targeted country, principal results, and decisional models. We then extracted and compared the dimensions adopted by vaccine frameworks across studies. RESULTS Fourteen studies (five systematic reviews and nine primary studies) were included. Several factors frequently influenced decision-makers' views on vaccines: the most frequent political-context factors considered were Importance of illness or problem, Vaccine characteristics, Resource use, and Feasibility. Others such as Values and preferences and Acceptability were less consistently reported. We did not find evidence on the reasons why a framework for vaccine adoption differs from that for decisions on the adoption of an intervention in general, such as the EtD. There are limited data on how dimensions are explained in practical factors and directly linked to coverage decisions. CONCLUSIONS This review summarises conceptual models and taxonomy of a heterogeneous and evolving area in health policy decisions. A shared and comprehensive framework on vaccine coverage remains to be achieved with its single dimensions (epidemiologic, effectiveness, economic, and social) valued differently across studies. A generic tool such as the EtD conceptualises all relevant dimensions, and might reduce inconsistencies.

[1]  C Wild,et al.  Decision support in vaccination policies. , 2009, Vaccine.

[2]  C. Kennedy,et al.  ‘Just that Little Bit of Doubt’: Scottish Parents', Teenage Girls' and Health Professionals' Views of the MMR, H1N1 and HPV Vaccines , 2014, International Journal of Behavioral Medicine.

[3]  N. Cameron,et al.  Financing vaccinations - the South African experience. , 2012, Vaccine.

[4]  Robert E Black,et al.  Global burden of childhood pneumonia and diarrhoea , 2013, The Lancet.

[5]  John P A Ioannidis,et al.  Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses? , 2012, BMJ : British Medical Journal.

[6]  Andrea R. Ashbaugh,et al.  The Decision to Vaccinate or Not during the H1N1 Pandemic: Selecting the Lesser of Two Evils? , 2013, PloS one.

[7]  J. Milstien,et al.  WHO policy development processes for a new vaccine: case study of malaria vaccines , 2010, Malaria Journal.

[8]  J. Ioannidis,et al.  Non-publication and delayed publication of randomized trials on vaccines: survey , 2014, BMJ : British Medical Journal.

[9]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[10]  Sarah E. Rosenbaum,et al.  Policymakers’ and other stakeholders’ perceptions of key considerations for health system decisions and the presentation of evidence to inform those considerations: an international survey , 2013, Health Research Policy and Systems.

[11]  A. Schuchat,et al.  Benefits from Immunization During the Vaccines for Children Program Era — United States, 1994–2013 , 2014, MMWR. Morbidity and mortality weekly report.

[12]  T. Cherian,et al.  A policy framework for accelerating adoption of new vaccines , 2010, Human vaccines.

[13]  Laura Amato,et al.  DECIDE: uno strumento per rendere trasparenti i criteri utilizzati per le decisioni in sanità , 2013 .

[14]  R. Hutubessy,et al.  Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal , 2011, BMC medicine.

[15]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[16]  T. F. Rinke de Wit,et al.  [AIDS treatment in Africa: the risk of antiretroviral resistance]. , 2007, Nederlands tijdschrift voor geneeskunde.

[17]  J. Ioannidis,et al.  Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement , 2004, Annals of Internal Medicine.

[18]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.

[19]  H. Rees,et al.  Developing evidence-based immunization recommendations and GRADE. , 2012, Vaccine.

[20]  J. Ioannidis,et al.  Non-publication and delayed publication of randomized trials on vaccines: a surveyLamberto Manzoli , 2014 .

[21]  L. Amato,et al.  [DECIDE: developing and evaluating communication strategies to support informed decisions and practice based on evidence]. , 2013, Recenti progressi in medicina.

[22]  Sarah E. Rosenbaum,et al.  Developing and evaluating communication strategies to support informed decisions and practice based on evidence (DECIDE): protocol and preliminary results , 2013, Implementation Science.

[23]  S. Opal,et al.  The controversy over H5N1 transmissibility research , 2013, Human vaccines & immunotherapeutics.

[24]  M. Kaddar,et al.  New vaccine adoption in lower-middle-income countries. , 2012, Health policy and planning.

[25]  M. Jit,et al.  A brief history of economic evaluation for human papillomavirus vaccination policy. , 2010, Sexual health.

[26]  M. Macadam,et al.  Drugs, sex, money and power: an HPV vaccine case study. , 2009, Health policy.

[27]  M. Robson,et al.  A Model for Enhancing Evidence-Based Capacity to Make Informed Policy Decisions on the Introduction of New Vaccines in the Americas: Paho's Provac Initiative , 2007, Public health reports.

[28]  H. Schünemann,et al.  Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). , 2011, Vaccine.

[29]  N. Cameron,et al.  The decision making process on new vaccines introduction in South Africa. , 2012, Vaccine.

[30]  J. Bryson,et al.  A systematic review of national immunization policy making processes. , 2010, Vaccine.

[31]  A. Mills,et al.  National decision-making on adopting new vaccines: a systematic review. , 2012, Health policy and planning.

[32]  H. Gallardo-Rincón,et al.  Strengthening vaccination policies in Latin America: an evidence-based approach. , 2013, Vaccine.

[33]  A. Brooks,et al.  Country planning for health interventions under development: lessons from the malaria vaccine decision-making framework and implications for other new interventions , 2012, Health policy and planning.

[34]  David P. Fidler,et al.  Negotiating Equitable Access to Influenza Vaccines: Global Health Diplomacy and the Controversies Surrounding Avian Influenza H5N1 and Pandemic Influenza H1N1 , 2010, PLoS medicine.